Last reviewed · How we verify
PET Acetate for Docetaxel Response Assessment in Hormone-Refractory Prostate Cancer
One purpose of this research study is to examine if a special type of imaging test, a positron emission tomography (PET) scan using the radioactive material \[C-11\] acetate, will be helpful in detecting prostate cancer lesions in subjects with castrate-resistant prostate cancer (CRPC). This PET scan will be combined with a computed tomography (CT) scan taken during the same imaging session. The other purpose of the PET-CT scan using \[C-11\] acetate (PET Acetate Scan) is to assist in identifying who is responding to the treatment (docetaxel chemotherapy).
Details
| Lead sponsor | Daniel Vaena |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 5 |
| Start date | 2010-05 |
| Completion | 2018-09 |
Conditions
- Castrate Resistant Prostate Cancer
- Prostate Cancer
Interventions
- PET Acetate scan
- Carbon-11 labeled Acetate
Primary outcomes
- Interpretation of PET Acetate scans — Time of enrollment up to one year
Standardized uptake values (mean and maximum SUVs) will be determined over the prostate bed and over any acetate-avid or CT-identified suspicious lesions. The change in these SUVs with treatment will be assessed, as well as the number of lesions. A blinded second reviewer from Nuclear Medicine will reviewed all baseline and response PET-acetate scans.
Countries
United States